Detail akcie BeiGene Sp ADS online

Business Summary: BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, BeOne Medicines AG (ADR) revenues increased 43% to $3.84B. Net income totaled $220.4M vs. loss of $492.9M. Revenues reflect Other segment increase of 42% to $59.2M, Other Collaboration segment increase of 5% to $22M, United States segment increase of 51% to $2.02B, China segment increase of 21% to $1.27B. Net Income reflects Interest Expense - Balancing value decrease of 25% to $49.6M (expense).